<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04926246</url>
  </required_header>
  <id_info>
    <org_study_id>1366-0024</org_study_id>
    <secondary_id>2020-005550-18</secondary_id>
    <nct_id>NCT04926246</nct_id>
  </id_info>
  <brief_title>A Study in Healthy Men to Find the Best Formulation of BI 685509 and to Test How it is Taken up in the Body</brief_title>
  <official_title>Formulation Selection and Subsequent Optimization of Oral Formulations of BI 685509 in Healthy Male Subjects (Open-label, Randomized, Single-dose Design Study in up to Three Parts; Trial Part 1: Five-period Crossover; Optional Trial Parts 2 &amp; 3: Four-period Crossover)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boehringer Ingelheim</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Boehringer Ingelheim</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The main objective of this trial is to select a formulation and to optimize the identified&#xD;
      formulation of BI 685509, if needed.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 1, 2021</start_date>
  <completion_date type="Anticipated">January 10, 2022</completion_date>
  <primary_completion_date type="Anticipated">January 10, 2022</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <intervention_model_description>Study in up to three parts:&#xD;
Trial part 1: five-period crossover Optional trial part 2: four-period crossover Optional trial part 3: four-period crossover</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>AUC0-∞ (area under the concentration-time curve of the analyte in plasma over the time interval from 0 extrapolated to infinity) (Part 1)</measure>
    <time_frame>up to 5 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>AUC0-∞ (area under the concentration-time curve of the analyte in plasma over the time interval from 0 extrapolated to infinity) (Part 2)</measure>
    <time_frame>up to 5 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>AUC0-∞ (area under the concentration-time curve of the analyte in plasma over the time interval from 0 extrapolated to infinity) (Part 3)</measure>
    <time_frame>up to 5 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>AUC0-tz (area under the concentration-time curve of the analyte in plasma over the time interval from 0 to the last quantifiable data point) (Part 1)</measure>
    <time_frame>up to 5 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUC0-tz (area under the concentration-time curve of the analyte in plasma over the time interval from 0 to the last quantifiable data point) (Part 2)</measure>
    <time_frame>up to 5 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUC0-tz (area under the concentration-time curve of the analyte in plasma over the time interval from 0 to the last quantifiable data point) (Part 3)</measure>
    <time_frame>up to 5 days</time_frame>
  </secondary_outcome>
  <number_of_arms>13</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Part 1: T1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>T1: Test Product M, under fasted conditions</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 1: T2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>T2: Test Product N, under fasted conditions</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 1: T3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>T3: Test Product O, under fasted conditions</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 1: T4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>T4: Test Product O, under fed conditions</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 1: R1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>R1: Reference Product X, under fasted conditions</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Optional Part 2: R2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>R2: Reference Product Y, under fasted conditions</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Optional Part 2: T5</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>T5: Test Product P, under fasted conditions</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Optional Part 2: T6</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>T6: Test Product P, under fed conditions</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Optional Part 2: T7</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>T7: Test Product Q, under fasted conditions</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Optional Part 3: R3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>R3: Reference Product Z, under fasted conditions</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Optional Part 3: T8</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>T8: Test Product S, under fasted conditions</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Optional Part 3: T9</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>T9: Test Product S, under fed conditions</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Optional Part 3: T10</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>T10: Test Product U, under fasted conditions</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BI 685509 oral formulation prototypes</intervention_name>
    <description>BI 685509</description>
    <arm_group_label>Optional Part 2: T5</arm_group_label>
    <arm_group_label>Optional Part 2: T6</arm_group_label>
    <arm_group_label>Optional Part 2: T7</arm_group_label>
    <arm_group_label>Optional Part 3: T10</arm_group_label>
    <arm_group_label>Optional Part 3: T8</arm_group_label>
    <arm_group_label>Optional Part 3: T9</arm_group_label>
    <arm_group_label>Part 1: T1</arm_group_label>
    <arm_group_label>Part 1: T2</arm_group_label>
    <arm_group_label>Part 1: T3</arm_group_label>
    <arm_group_label>Part 1: T4</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BI 685509 standard oral formulation</intervention_name>
    <description>BI 685509</description>
    <arm_group_label>Optional Part 2: R2</arm_group_label>
    <arm_group_label>Optional Part 3: R3</arm_group_label>
    <arm_group_label>Part 1: R1</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Healthy male subjects according to the assessment of the investigator, as based on a&#xD;
             complete medical history including a physical examination, vital signs (Blood pressure&#xD;
             (BP), Pulse rate (PR)), 12-lead Electrocardiogram (ECG), and clinical laboratory tests&#xD;
&#xD;
          -  Age of 18 to 55 years (inclusive) at the time of signing informed consent&#xD;
&#xD;
          -  Body mass index (BMI) of 18.5 to 29.9 kg/m2 (inclusive) at the time of signing&#xD;
             informed consent&#xD;
&#xD;
          -  Signed and dated written informed consent prior to admission to the study, in&#xD;
             accordance with Good Clinical Practice (GCP) and local legislation&#xD;
&#xD;
          -  Subjects who are sexually active must use with their partner, highly effective&#xD;
             contraception from the time of administration of trial medication until 30 days after&#xD;
             administration of trial medication. Adequate methods are:&#xD;
&#xD;
               -  Condoms plus use of hormonal contraception by the female partner that started at&#xD;
                  least 2 months prior to administration of trial medication (e.g., implants,&#xD;
                  injectables, combined oral or vaginal contraceptives, intrauterine device) or&#xD;
&#xD;
               -  Condoms plus surgical sterilization (vasectomy at least 1 year prior to&#xD;
                  enrolment) or&#xD;
&#xD;
               -  Condoms plus surgically sterilised partner (including hysterectomy) or&#xD;
&#xD;
               -  Condoms plus intrauterine device or&#xD;
&#xD;
               -  Condoms plus partner of non-childbearing potential (including homosexual men)&#xD;
                  Subjects are required to use condoms to prevent unintended exposure of the&#xD;
                  partner (both, male and female) to the study drug via seminal fluid. Male&#xD;
                  subjects should use a condom throughout the study and for 30 days after last&#xD;
                  Investigational Medicinal Product (IMP) administration. Alternatively, true&#xD;
                  abstinence is acceptable when it is in line with the subject's preferred and&#xD;
                  usual lifestyle. If a subject is usually not sexually active but becomes active&#xD;
                  with their partner, they must comply with the contraceptive requirements detailed&#xD;
                  above.&#xD;
&#xD;
        Male subjects should not donate sperm for the duration of the study and for at least 30&#xD;
        days after last IMP administration.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Any finding in the medical examination (including Blood pressure (BP), Pulse rate (PR)&#xD;
             or Electrocardiogram (ECG)) deviating from normal and assessed as clinically relevant&#xD;
             by the investigator&#xD;
&#xD;
          -  Repeated measurement of systolic blood pressure outside the range of 100 to 140 mmHg,&#xD;
             diastolic blood pressure outside the range of 60 to 90 mmHg, or pulse rate outside the&#xD;
             range of 40 to 100 bpm at screening and pre-dose of first period&#xD;
&#xD;
          -  Any laboratory value outside the reference range that the investigator considers to be&#xD;
             of clinical relevance&#xD;
&#xD;
          -  Any evidence of a concomitant disease assessed as clinically relevant by the&#xD;
             investigator, including not resolved post-vaccination reactions&#xD;
&#xD;
          -  Gastrointestinal, hepatic, renal, respiratory, cardiovascular, metabolic,&#xD;
             immunological, dermatological or hormonal disorders&#xD;
&#xD;
          -  Cholecystectomy or other surgery of the gastrointestinal tract that could interfere&#xD;
             with the pharmacokinetics of the trial medication (except appendectomy or simple&#xD;
             hernia repair, unless within the last 12 months)&#xD;
&#xD;
          -  Diseases of the central nervous system (including but not limited to any kind of&#xD;
             seizures or stroke), and other relevant neurological or psychiatric disorders&#xD;
&#xD;
          -  History of relevant orthostatic hypotension, fainting spells, or blackouts Further&#xD;
             exclusion criteria apply.&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Quotient Sciences</name>
      <address>
        <city>Nottingham</city>
        <zip>NG11 6JS</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sharan Sidhu</last_name>
      <phone>0115 974 9000</phone>
      <email>Sharan.Sidhu@quotientsciences.com</email>
    </contact>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <link>
    <url>http://www.mystudywindow.com</url>
    <description>Related Info</description>
  </link>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>June 14, 2021</study_first_submitted>
  <study_first_submitted_qc>June 14, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">June 15, 2021</study_first_posted>
  <last_update_submitted>November 3, 2021</last_update_submitted>
  <last_update_submitted_qc>November 3, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 4, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>Clinical studies sponsored by Boehringer Ingelheim, phases I to IV, interventional and non-interventional, are in scope for sharing of the raw clinical study data and clinical study documents, except for the following exclusions:&#xD;
studies in products where Boehringer Ingelheim is not the license holder;&#xD;
studies regarding pharmaceutical formulations and associated analytical methods, and studies pertinent to pharmacokinetics using human biomaterials;&#xD;
studies conducted in a single center or targeting rare diseases (because of limitations with anonymization).&#xD;
For more details refer to: https://www.mystudywindow.com/msw/datasharing</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

